A recent transaction that is perhaps more comparable is Biogen's buyout of rare disease (neuromuscular) drug developer Reata Pharmaceuticals for US$7.3b. Reata has a FDA-approved drug (Skyclarys) for Friedrich's Ataxia which has a lower incidence than Retts and another drug only in phase I as well as some preclinical assets.
A significant difference is that Reata would not have licensed out Skyclarys but on the flip side Neuren has 2591 completing phase II which has blockbuster potential.
https://www.fiercepharma.com/pharma/how-biogen-outbid-rival-pharma-claim-reata-its-own-73b
https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-reata-pharmaceuticals
Merck to acquire Prometheus in a US$ 10.8 b deal, page-11
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.82 |
Change
0.020(0.10%) |
Mkt cap ! $2.528B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.04 | $19.59 | $854.8K | 43.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 72 | $19.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.83 | 26 | 1 |
View Market Depth
| Last trade - 10.26am 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.76 |
Change
0.020 ( 0.38 %) |
||||
| Open | High | Low | Volume | ||
| $19.99 | $20.04 | $19.60 | 12062 | ||
| Last updated 10.43am 18/06/2024 ? | |||||
| NEU (ASX) Chart |
